Brought to you by 
NeoGenesis, Oxford GlycoSciences in drug discovery deal
26 Jun 2001
Executive Summary
NeoGenesis (applied genomics and chemistry) will apply its high-throughput screening technologies to several thousand of Oxford GlycoSciences' (proteomics-based drug discovery) protein targets to identify lead drug candidates.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NeoGenesis, Oxford GlycoSciences in drug discovery deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice